Primary Sjögren's syndrome and the type I interferon system

Current Pharmaceutical Biotechnology

Volumn 13, Issue 10, 2012, Pages 2054-2062

  Nordmark, Gunnel ^a   Eloranta, Maija Leena ^a   Rönnblom, Lars ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

Immune complexes; Interferon alpha; IRF5; Minor salivary glands; Plasmacytoid dendritic cells; Primary Sj gren's syndrome; SSA SSB; STAT4; Type I interferon

Indexed keywords

ALPHA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 5; STAT4 PROTEIN;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ARTICLE; DISEASE MODEL; DNA POLYMORPHISM; GENE EXPRESSION; GENETIC ASSOCIATION; HUMAN; INTERFERON PRODUCTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMACYTOID DENDRITIC CELL; RISK FACTOR; SALIVARY GLAND; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; UPREGULATION;

AUTOANTIBODIES; DENDRITIC CELLS; HUMANS; INTERFERON TYPE I; SALIVARY GLANDS, MINOR; SJOGREN'S SYNDROME;

EID: 84865352321     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112802273290     Document Type: Article

References (69)

1. Jonsson, R.; Bolstad, A.I.; Brokstad, K.A.; Brun, J.G. Sjögren's syndrome-a plethora of clinical and immunological phenotypes with a complex genetic background. Ann. N.Y. Acad. Sci. 2007, 1108 433-447.
2. Båve, U.; Nordmark, G.; Lövgren, T.; Rönnelid, J.; Cajander, S.; Eloranta, ML.; Alm, G.V.; Rönnblom, L. Activation of the type I interferon system in primary Sjögren's syndrome-a possible etiopathogenic mechanism. Arthritis Rheum. 2005, 52(4), 1185-1195.
3. Korman, B.D.; Alba, M.I.; Le, J.M.; Alevizos, I.; Smith, J.A.; Nikolov, N.P.; Kastner, D.L.; Remmers, E.F.; Illei, G.G. Variant form of STAT4 is associated with primary Sjögren's syndrome. Genes Immun., 2008, 9(3), 267-270.
4. Miceli-Richard, C.; Comets, E.; Loiseau, P.; Puechal, X.; Hachulla, E.; Mariette, X. Association of an IRF5 gene functional polymorphism with Sjögren's syndrome. Arthritis Rheum., 2007, 56(12), 3989-3994.
5. Nordmark, G.; Kristjansdottir, G.; Theander, E.; Eriksson, P.; Brun, J.G.; Wang, C.; Padyukov, L.; Truedsson, L.; Alm, G.; Eloranta, ML.; Jonsson, R.; Rönnblom, L.; Syvänen, AC. Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. Genes Immun. 2009, 10(1), 68-76.
6. Pestka, S.; Krause, C.D.; Walter, M.R. Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. 2004, 202 8-32.
7. Fitzgerald-Bocarsly, P.; Dai, J.; Singh, S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. Cytokine Growth Factor Rev. 2008, 19(1), 3-19.
8. Gilliet, M.; Cao, W.; Liu, Y.J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat. Rev. Immunol. 2008, 8(8), 594-606.
9. Takaoka, A.; Yanai, H. Interferon signalling network in innate defence. Cell Microbiol. 2006, 8(6), 907-922.
10. Theofilopoulos, A.; Baccala, R.; Beutler, B.; Kono, D.H. Type I interferons (a/b) in immunity and autoimmunity. Annu. Rev. Immunol. 2005, 23 307-336.
11. Gota, C.; Calabrese, L. Induction of clinical autoimmune disease by therapeutic interferon-. Autoimmunity 2003, 36(8), 511-518.
12. Rönnblom, L.; Alm, G.V.; Öberg, K.E. Autoimmunity after alphainterferon therapy for malignant carcinoid tumors. Ann. Intern. Med. 1991, 115(3), 178-183.
13. James, J.; Harley, J.; Scofield, R.H. Role of viruses in systemic lupus erythematosus and Sjögren syndrome. Curr. Opin. Rheumatol. 2001, 13(5), 370-376.
14. Verbaan, H.; Carlson, J.; Eriksson, S.; Larsson, Å.; Liedholm, R.; Manthorpe, R.; Tabery, H.; Widell, A.; Lindgren, S. Extrahepatic manifestations of chronic hepatitis C infection and the interrelationship between primary Sjögren's syndrome and hepatitis C in Swedish patients. J. Intern. Med. 1999, 245(2), 127-132.
15. Vitali, C.; Bombardieri, S.; Jonsson, R.; Moutsopoulos, H.M.; Alexander, E.L.; Carsons, S.E.; Daniels, T.E.; Fox, P.C.; Fox, R.I.; Kassan, S.S.; Pillemer, S.R.; Talal, N.; Weisman, M.H.; European study group on classification criteria for Sjögren's syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann. Rheum. Dis. 2002, 61(6), 554-558.
16. Vallin, H.; Blomberg, S.; Alm, G.V.; Cederblad, B.; Rönnblom, L. Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-) production acting on leuco cytes resembling immature dendritic cells. Clin. Exp. Immunol. 1999, 115(1), 196-202.
17. Ohlsson, M.; Jonsson, R.; Brokstad, K.A. Subcellular redistribution and surface exposure of the Ro52, Ro60 and La48 autoantigens during apoptosis in human ductal epithelial cells: a possible mechanism in the pathogenesis of Sjögren's syndrome. Scand J. Immunol. 2002, 56(5), 456-469.
18. Lövgren, T.; Eloranta, ML.; Kastner, B.; Wahren-Herlenius, M.; Alm, G.V.; Rönnblom, L. Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen-and Sjögren's syndrome autoantigen-associated RNA. Arthritis Rheum. 2006, 54(6), 1917-1927.
19. Rönnblom, L.; Alm, G.V. An ethiopathogenic role for the type I IFN system in SLE. Trends immunol. 2001, 22(8), 427-431.
20. Rönnblom, L.; Eloranta, M.L.; Alm, G.V. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 2006, 54(2), 408-420.
21. Candon, S.; Gottenberg, J.E.; Bengoufa, D.; Chatenoud, L.; Mariette, X. Quantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activity. Ann. Rheum. Dis. 2009, 68(7), 1208-1212.
22. Eloranta, ML.; Lövgren, T.; Finke, D.; Mathsson, L.; Rönnelid, J.; Kastner, B.; Alm, G.; Rönnblom, L. Regulation of the interferonalpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells. Arthritis Rheum. 2009, 60(8), 2418-1427.
23. Wildenberg, M.E.; van Helden-Meeuwsen, C.G.; van de Merwe, J.P.; Drexhage, H.A.; Versnel, M.A. Systemic increase in type I interferon activity in Sjögren's syndrome: A putative role for plasmacytoid dendritic cells. Eur. J. Immunol. 2008, 38(7), 2024-2033.
24. Zheng, L.; Zhang, Z.; Yu, C.; Tu, L.; Zhong, L.; Yang, C. Association between IFN-and primary Sjogren's syndrome. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2009, 107(1), e12-18.
25. Reksten, T.R.; Jonsson, M.V.; Szyszko, E.A.; Brun, J.G.; Jonsson, R.; Brokstad, K.A. Cytokine and autoantibody profiling related to histopathological features in primary Sjogren's syndrome. Rheumatology. 2009, 48(9), 1102-1106.
26. Hua, J.; Kirou, K.; Lee, C.; Crow, M.K. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006, 54(6), 1906-1916.
27. Mavragani, C.P.; Niewold, T.B.; Moutsopoulos, N.M.; Pillemer, S.R.; Wahl, S.M.; Crow, M.K. Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept. Arthritis Rheum. 2007, 56(12), 3995-4004.
28. Niewold, T.B.; Rivera, T.L.; Buyon, J.P.; Crow, M.K. Serum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus. Arthritis Rheum. 2008, 58(2), 541-546.
29. Båve, U.; Vallin, H.; Alm, G.V.; Rönnblom, L. Activation of natural interferon-producing cells by apoptotic U937 combined with lupus IgG and its regulation by cytokines. J. Autoimmun. 2001, 17(1), 71-80.
30. Emamian, E.S.; Leon, J.M.; Lessard, C.J.; Grandits, M.; Baechler, E.C.; Gaffney, P.M.; Segal, B.; Rhodus, N.L.; Moser, K.L. Peripheral blood gene expression profiling in Sjögren's syndrome. Genes Immun. 2009, 10(4), 285-296.
31. Vogelsang, P.; Brun, J.G.; Oijordsbakken, G.; Skarstein, K.; Jonsson, R.; Appel, S. Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjogren's syndrome. Ann. Rheum. Dis. 2010, 69(6), 1235-1238.
32. Blomberg, S.; Eloranta, M.L.; Magnusson, M.; Alm, G.V.; Rönnblom, L. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-aaaby plasmacytoid dendritic cells in systemic lupus erythematosus., Arthritis Rheum. 2003, 48(9), 2524-2532.
33. Rowe, D.; Griffiths, M.; Stewart, J.; Novick, D.; Beverley, P.C.; Isenberg, D.A. HLA class I and II, interferon, interleukin 2, and the interleukin 2 receptor expression on labial biopsy specimens from patients with Sjögren's syndrome. Ann. Rheum. Dis. 1987, 46(8), 580-586.
34. Gottenberg, JE.; Cagnard, N.; Lucchesi, C.; Letourneur, F.; Mistou, S.; Lazure, T.; Jacques, S.; Ba, N.; Ittah, M.; Lepajolec, C.; Labetoulle, M.; Ardizzone, M.; Sibilia, J.; Fournier, C.; Chiocchia, G.; Mariette, X. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome. Proc. Natl. Acad. Sci. USA 2006, 103(8), 2770-2775.
35. Amft, N.; Curnow, S.J.; Scheel-Toellner, D.; Devadas, A.; Oates, J.; Crocker, J.; Hamburger, J.; Ainsworth, J.; Matthews, J.; Salmon, M.; Bowman, S.J.; Buckley, C.D. Ectopic expression of the B cell attracting chemokine BCA-1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center-like structures in Sjogren's syndrome. Arthritis Rheum. 2001, 44(11), 2633-2641.
36. Ogawa, N.; Kawanami, T.; Shimoyama, K.; Ping, L.; Sugai, S. Expression of interferon-inducible T cell EEEchemoattractant (CXCL11) in the salivary glands of patients with Sjögren's syndrome. Clin. Immunol. 2004, 112(3), 235-238.
37. Vanbervliet, B.; Bendriss-Vermare, N.; Massacrier, C.; Homcy, B.; de Bouteiller, O.; Briere, F.; Trinchieri, G.; Caux, C. The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J. Exp. Med. 2003, 198(5), 823-830.
38. Salomonsson, S.; Larsson, P.; Tengner, P.; Mellquist, E.; Hjelmström, P.; Wahren-Herlenius, M. Expression of the B cell-attracting chemokine CXCL13 in the target organ and autoantibody production in ectopic lymphoid tissue in the chronic infammatory disease Sjögren's syndrome. Scand J. Immunol. 2002, 55(4), 336-342.
39. Hjelmervik, T.O.; Petersen, K.; Jonassen, I.; Jonsson, R.; Bolstad, A.I. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjögren's syndrome patients from healthy control subjects. Arthritis Rheum. 2005, 52(5), 1534-1544.
40. Hu, S.; Wang, J.; Meijer, J.; Ieong, S.; Xie, Y.; Yu, T.; Zhou, H.; Henry, S.; Vissink, A.; Pijpe, J.; Kallenberg, C.; Elashoff, D.; Loo, J.A.; Wong, D.T. Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. Arthritis Rheum. 2007, 56(11), 3588-3600.
41. Grewal, I.S.; Flavell, R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 1998, 16 111-135.
42. Ohlsson, M.; Szodoray, P.; Loro, L.L.; Johannessen, A.C.; Jonsson, R. CD40, CD154, Bax and Bcl-2 expression in Sjögren's syndrome salivary gland cells: a putative anti-apoptotic role during its effector phases. Scand J. Immunol. 2002, 56(6), 561-571.
43. Lavie, F.; Miceli-Richard, C.; Quillard, J.; Roux, S.; Leclerc, P.; Mariette, X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J. Pathol. 2004, 202(4), 496-502.
44. Ittah, M.; Miceli-Richard, C.; Gottenberg, JE.; Lavie, F.; Lazure, T.; Ba, N.; Sellam, J.; Lepajolec, C.; Mariette, X. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. Arthritis Res. Ther. 2006, 8(2), R51.
45. Ittah, M.; Miceli-Richard, C.; Gottenberg, J.E.; Sellam, J.; Eid, P.; Lebon, P.; Pallier, C.; Lepajolec, C.; Mariette, X. Viruses induce high expression of BAFF by salivary gland epithelial cells through TLR-and type-I IFN-dependent and-independent pathways. Eur. J. Immunol. 2008, 38(4), 1058-1064.
46. Chawla-Sarkar, M.; Lindner, D.J.; Liu, Y.F.; Williams, B.R.; Sen, G.C.; Silverman, R.H.; Borden, E.C. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003, 8(3), 237-249.
47. Kong, L.; Ogawa, N.; Nakabayashi, T.; Liu, G.T.; d'Souza, E.; McGuff, H.S.; Guerrero, D.; Talal, N.; Dang, H. Fas and Fas ligand expression in the salivary glands of patients with primary Sjögren's syndrome. Arthritis Rheum. 1997, 40(1), 87-97.
48. Baechler, E.C.; Batliwalla, F.M.; Karypis, G.; Gaffney, P.M.; Ortmann, W.A.; Espe, K.J.; Shark, K.B.; Grande, W.J.; Hughes, K.M.; Kapur, V.; Gregersen, P.K.; Behrens, T.W. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc. Natl. Acad. Sci. USA 2003, 100(5), 2610-2615.
49. Strandberg, L.; Ambrosi, A.; Espinosa, A.; Ottosson, L.; Eloranta, ML.; Zhou, W.; Elfving, A.; Greenfield, E.; Kuchroo, V.K.; Wahren-Herlenius, M. Interferon-alpha induces up-regulation and nuclear translocation of the Ro52 autoantigen as detected by a panel of novel Ro52-specific monoclonal antibodies. J. Clin. Immunol. 2008, 28(3), 220-231.
50. Salomonsson, S.; Wahren-Herlenius, M. Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels of circulating antibodies in sera of patients with Sjogren's syndrome. Scand J. Rheumatol. 2003, 32(2), 79-82.
51. Espinosa, A.; Dardalhon, V.; Brauner, S.; Ambrosi, A.; Higgs, R.; Quintana, F.J.; Sjöstrand, M.; Eloranta, ML.; Gabhann, J.N.; Winqvist, O.; Sundelin, B.; Jefferies, C.A.; Rozell, B.; Kuchroo, V.K.; Wahren-Herlenius, M. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. Clin. Exp. Med. 2009, 206(8), 1661-1671.
52. Dieudé, P.; Guedj, M.; Wipff, J.; Avouac, J.; Fajardy, I.; Diot, E.; Granel, B.; Sibilia, J.; Cabane, J.; Mouthon, L.; Cracowski, J.L.; Carpentier, P.H.; Hachulla, E.; Meyer, O.; Kahan, A.; Boileau, C.; Allanore, Y. Association between the IRF5 rs2004640 functional polymorphism and systemic sclerosis: a new perspective for pulmonary fibrosis. Arthritis Rheum. 2009, 60(1), 225-233.
53. Remmers, E.F.; Plenge, R.M.; Lee, A.T.; Graham, R.R.; Hom, G.; Behrens, T.W.; de Bakker, P.I.; Le, J.M.; Lee, HS.; Batliwalla, F.; Li, W.; Masters, S.L.; Booty, M.G.; Carulli, J.P.; Padyukov, L.; Alfredsson, L.; Klareskog, L.; Chen, W.V.; Amos, C.I.; Criswell, L.A.; Seldin, M.F.; Kastner, D.L.; Gregersen, P.K. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 2007, 357(10), 977-986.
54. Rueda, B.; Broen, J.; Simeon, C.; Hesselstrand, R.; Diaz, B.; Suárez, H.; Ortego-Centeno, N.; Riemekasten, G.; Fonollosa, V.; Vonk, M.C.; van den Hoogen, F.H.; Sanchez-Róman, J.; Aguirre-Zamorano, M.A.; García-Portales, R.; Pros, A.; Camps, M.T.; Gonzales-Gay, M.A.; Coenen, M.J.; Airo, P.; Beretta, L.; Scorza, R.; van Laar, J.; Gonzalez-Escribano, M.F.; Nelson, J.L.; Radstake, T.R.; Martin, J. The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Hum. Mol. Genet. 2009, 18(11), 2071-2077.
55. Sigurdsson, S.; Nordmark, G.; Göring, H.; Lindroos, K.; Wiman, AC.; Sturfelt, G.; Jönsen, A.; Rantapää-Dahlqvist, S.; Möller, B.; Kere, J.; Koskenmies, S.; Widen, E.; Eloranta, ML.; Julkunen, H.; Kristjansdottir, H.; Steinsson, K.; Alm, G.; Rönnblom, L.; Syvänen, AC. Polymorphisms in the tyrosine kinas 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 2005, 76(3), 528-537.
56. Sigurdsson, S.; Padyukov, L.; Kurreeman, F.A.; Liljedahl, U.; Wiman, AC.; Alfredsson, L.; Toes, R.; Rönnelid, J.; Klareskog, L.; Huizinga, T.W.; Alm, G.; Syvänen, AC.; Rönnblom, L. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum. 2007, 56(7), 2202-2210.
57. Dideberg, V.; Kristjansdottir, G.; Milani, L.; Libioulle, C.; Sigurdsson, S.; Louis, E.; Wiman, AC.; Vermeire, S.; Rutgeerts, P.; Belaiche, J.; Franchimont, D.; van Gossum, A.; Bours, V.; Syvänen, AC. An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel disease. Hum. Mol. Genet. 2007, 16(24), 3008-3016.
58. Kristjansdottir, G.; Sandling, J.K.; Bonetti, A.; Roos, I.M.; Milani, L.; Wang, C.; Gustafsdottir, S.M.; Sigurdsson, S.; Lundmark, A.; Tienari, P.J.; Koivisto, K.; Elovaara, I.; Pirttilä, T.; Reunanen, M.; Peltonen, L.; Saarela, J.; Hillert, J.; Olsson, T.; Landegren, U.; Alcina, A.; Fernandez, O.; Leyva, L.; Guerrero, M.; Lucas, M.; Izquierdo, G.; Matesanz, F.; Syvänen, AC. Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations. J. Med. Genet. 2008, 45(6), 362-369.
59. Sigurdsson, S.; Göring, H.H.; Kristjansdottir, G.; Milani, L.; Nordmark, G.; Sandling, J.K.; Eloranta, ML.; Feng, D.; Sangster-Guity, N.; Gunnarsson, I.; Svenungsson, E.; Sturfelt, G.; Jönsen, A.; Truedsson, L.; Barnes, B.J.; Alm, G.; Rönnblom, L.; Syvänen, AC. Comprehensive evaluation of the genetic variants of interferon regulatory factor 5 (IRF5) reveals a novel 5 bp length polymorphism as strong risk factor for systemic lupus erythematosus. Hum. Mol. Genet. 2008, 17(6), 872-881.
60. Niewold, T.B.; Kelly, J.A.; Flesch, M.H.; Espinoza, L.R.; Harley, J.B.; Crow, M.K. Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients. Arthritis Rheum. 2008, 58(8), 2481-2487.
61. Sigurdsson, S.; Nordmark, G.; Garnier, S.; Grundberg, E.; Kwan, T.; Nilsson, O.; Eloranta, ML.; Gunnarsson, I.; Svenungsson, E.; Sturfelt, G.; Bengtsson, A.A.; Jönsen, A.; Truedsson, L.; Rantapää-Dahlqvist, S.; Eriksson, C.; Alm, G.; Göring, H.H.; Pastinen, T.; Syvänen, AC.; Rönnblom, L. A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with antidsDNA and shows additive effects with two risk alleles of IRF5. Hum. Mol. Genet. 2008, 17(18), 2868-2876.
62. Kariuki, S.N.; Kirou, K.A.; MacDermott, E.J.; Barillas-Arias, L.; Crow, M.K.; Niewold, T.B. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J. Immunol. 2009, 182(1), 34-38.
63. Goules, A.; Masouridi, S.; Tzioufas, A.; Ioannidis, J.P.; Skopouli, F.N.; Moutsopoulos, H.M. Clinically significant and biopsydocumented renal involvement in primary Sjögren's syndrome. Medicine 2000, 79(4), 241-249.
64. Greenberg, S.A.; Pinkus, J.L.; Pinkus, G.S.; Burleson, T.; Sanoudou, D.; Tawil, R.; Barohn, R.J.; Saperstein, D.S.; Briemberg, H.R.; Ericsson, M.; Park, P.; Amato, A.A. Interferon-a/b-mediated innate immune mechanisms in dermatomyositis. Ann. Neurol. 2005, 57(5), 664-678.
65. Lande, R.; Giacomini, E.; Serafini, B.; Rosicarelli, B.; Sebastiani, G.D.; Minisola, G.; Tarantino, U.; Riccieri, V.; Valesini, G.; Coccia, E.M. Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis. J. Immunol. 2004, 173(4), 2815-2824.
66. Nestle, F.O.; Conrad, C.; Tun-Kyi, A.; Homey, B.; Gombert, M.; Boyman, O.; Burg, G.; Liu, Y.J.; Gilliet, M. Plasmacytoid predendritic cells initiate psoriasis through interferon-cccproduction. J. Exp. Med. 2005, 202(1), 135-143.
67. Rihl, M.; Ulbricht, K.; Schmidt, R.E.; Witte, T. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. Rheumatology 2009, 48(7), 796-799.
68. Wallace, D.J.; Petri, M.; Olsen, N.; Kirou, K.; Dennis, G.; Yao, Y.; Jallal, B.; Coyle, A.; Zeng, L.; White, B. MEDI-545, an antiinterferon alpha monoclonal antibody, shows evidence of clinical activity in systemic lupus erythematosus. Arthritis Rheum. 2007, 56(Suppl.), S562-S563.
69. Yao, Y.; Richman, L.; Higgs, B.W.; Morehouse, C.A.; de los Reyes, M.; Brohawn, P.; Zhang, J.; White, B.; Coyle, A.J.; Kiener, P.A.; Jallal, B. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferonalpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum. 2009, 60(6), 1785-1796.